Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66] : corrigendum
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2022
|
| In: |
Annals of oncology
Year: 2022, Jahrgang: 33, Heft: 4, Pages: 454-454 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2022.01.005 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2022.01.005 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S092375342200014X |
| Verfasserangaben: | S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1841086177 | ||
| 003 | DE-627 | ||
| 005 | 20241205134104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230403s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.01.005 |2 doi | |
| 035 | |a (DE-627)1841086177 | ||
| 035 | |a (DE-599)KXP1841086177 | ||
| 035 | |a (OCoLC)1475285355 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Novello, Silvia |e VerfasserIn |0 (DE-588)1339521407 |0 (DE-627)1899154280 |4 aut | |
| 245 | 1 | 0 | |a Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” |b [Annals of Oncology 33 (2022) 57-66] : corrigendum |c S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti |
| 264 | 1 | |c April 2022 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 25. Januar 2022, Artikelversion: 18. März 2022 | ||
| 500 | |a Gesehen am 20.08.2024 | ||
| 700 | 1 | |a Torri, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grohé, Christian |e VerfasserIn |0 (DE-588)1222446383 |0 (DE-627)1741490987 |4 aut | |
| 700 | 1 | |a Kurz, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Serke, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wehler, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meyer, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ladage, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geissler, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colantonio, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cauchi, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stoelben, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ceribelli, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kropf-Sanchen, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valmadre, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borra, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schena, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morabito, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Santo, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gregorc, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chiari, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reck, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid-Bindert, Gerald |d 1969- |e VerfasserIn |0 (DE-588)121300129 |0 (DE-627)081214170 |0 (DE-576)292636024 |4 aut | |
| 700 | 1 | |a Folprecht, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Griesinger, Frank |e VerfasserIn |0 (DE-588)1080408916 |0 (DE-627)844436305 |0 (DE-576)453541747 |4 aut | |
| 700 | 1 | |a Follador, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pedrazzoli, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bearz, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Caffo, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dickgreber, N. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Irtelli, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wiest, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Monica, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Porcu, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 700 | 1 | |a Scagliotti, G. V. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 33(2022), 4, Seite 454-454 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” [Annals of Oncology 33 (2022) 57-66] : corrigendum |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:4 |g pages:454-454 |g extent:1 |a Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” [Annals of Oncology 33 (2022) 57-66] : corrigendum |
| 787 | 0 | 8 | |i Errata zu |a Novello, Silvia |t International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer |d 2022 |w (DE-627)1841086320 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2022.01.005 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S092375342200014X |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240820 | ||
| 993 | |a Editorial | ||
| 994 | |a 2022 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |e 60000PM108614913 |k 0/60000/ |p 35 |y j | ||
| 998 | |g 121300129 |a Schmid-Bindert, Gerald |m 121300129:Schmid-Bindert, Gerald |d 60000 |e 60000PS121300129 |k 0/60000/ |p 23 | ||
| 999 | |a KXP-PPN1841086177 |e 4569016057 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"1 S."}],"id":{"doi":["10.1016/j.annonc.2022.01.005"],"eki":["1841086177"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online verfügbar: 25. Januar 2022, Artikelversion: 18. März 2022","Gesehen am 20.08.2024"],"relHost":[{"disp":"Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” [Annals of Oncology 33 (2022) 57-66] : corrigendumAnnals of oncology","recId":"320428796","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1990 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"part":{"issue":"4","extent":"1","volume":"33","text":"33(2022), 4, Seite 454-454","pages":"454-454","year":"2022"},"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"person":[{"role":"aut","family":"Novello","display":"Novello, Silvia","given":"Silvia"},{"family":"Torri","given":"V.","display":"Torri, V.","role":"aut"},{"given":"Christian","display":"Grohé, Christian","family":"Grohé","role":"aut"},{"family":"Kurz","display":"Kurz, S.","given":"S.","role":"aut"},{"role":"aut","given":"M.","display":"Serke, M.","family":"Serke"},{"role":"aut","given":"T.","display":"Wehler, T.","family":"Wehler"},{"family":"Meyer","given":"A.","display":"Meyer, A.","role":"aut"},{"display":"Ladage, D.","given":"D.","family":"Ladage","role":"aut"},{"role":"aut","display":"Geissler, M.","given":"M.","family":"Geissler"},{"display":"Colantonio, I.","given":"I.","family":"Colantonio","role":"aut"},{"display":"Cauchi, C.","given":"C.","family":"Cauchi","role":"aut"},{"role":"aut","family":"Stoelben","given":"E.","display":"Stoelben, E."},{"role":"aut","display":"Ceribelli, A.","given":"A.","family":"Ceribelli"},{"role":"aut","display":"Kropf-Sanchen, C.","given":"C.","family":"Kropf-Sanchen"},{"family":"Valmadre","given":"G.","display":"Valmadre, G.","role":"aut"},{"family":"Borra","display":"Borra, G.","given":"G.","role":"aut"},{"role":"aut","given":"M.","display":"Schena, M.","family":"Schena"},{"display":"Morabito, A.","given":"A.","family":"Morabito","role":"aut"},{"family":"Santo","given":"A.","display":"Santo, A.","role":"aut"},{"display":"Gregorc, V.","given":"V.","family":"Gregorc","role":"aut"},{"display":"Chiari, R.","given":"R.","family":"Chiari","role":"aut"},{"role":"aut","given":"M.","display":"Reck, M.","family":"Reck"},{"role":"aut","given":"Gerald","display":"Schmid-Bindert, Gerald","family":"Schmid-Bindert"},{"display":"Folprecht, G.","given":"G.","family":"Folprecht","role":"aut"},{"role":"aut","given":"Frank","display":"Griesinger, Frank","family":"Griesinger"},{"role":"aut","family":"Follador","display":"Follador, A.","given":"A."},{"family":"Pedrazzoli","given":"P.","display":"Pedrazzoli, P.","role":"aut"},{"family":"Bearz","display":"Bearz, A.","given":"A.","role":"aut"},{"role":"aut","display":"Caffo, O.","given":"O.","family":"Caffo"},{"display":"Dickgreber, N. J.","given":"N. J.","family":"Dickgreber","role":"aut"},{"role":"aut","family":"Irtelli","display":"Irtelli, L.","given":"L."},{"role":"aut","family":"Wiest","given":"G.","display":"Wiest, G."},{"role":"aut","display":"Monica, V.","given":"V.","family":"Monica"},{"role":"aut","display":"Porcu, L.","given":"L.","family":"Porcu"},{"display":"Manegold, Christian","given":"Christian","family":"Manegold","role":"aut"},{"family":"Scagliotti","given":"G. V.","display":"Scagliotti, G. V.","role":"aut"}],"origin":[{"dateIssuedDisp":"April 2022","dateIssuedKey":"2022"}],"name":{"displayForm":["S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti"]},"recId":"1841086177","title":[{"title":"Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”","title_sort":"Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”","subtitle":"[Annals of Oncology 33 (2022) 57-66] : corrigendum"}],"language":["eng"]} | ||
| SRT | |a NOVELLOSILCORRIGENDU2022 | ||